QUEBEC CITY, June 22, 2011 /PRNewswire/ — Asmacure Ltee, a
clinical-stage biopharmaceutical company focused on the development
of nicotinic receptor agonists for the treatment of asthma and
other inflammatory diseases, announced today that CEO Martin
Driscoll will be presenting at the 2011 BIO Business Forum during
the annual BIO International Convention. Mr. Driscoll’s
presentation will be given in the Georgetown Room of the Walter E.
Washington Convention Center in Washington, DC on Wednesday, June
29, 2011 at 2:15 p.m. EDT. The presentation will include an
overview of the company’s nictonic acetylcholine receptor
technology, with emphasis on the lead development program for the
treatment of asthma, ASM-024.
About Asmacure
Ltee
Asmacure Ltee is a clinical-stage biopharmaceutical company
focused on the development of nicotinic receptor agonists for the
treatment of asthma and other inflammatory diseases. The
company’s lead compound, ASM-024, is a novel molecular entity
currently in clinical development for the treatment of asthma.
ASM-024 utilizes Asmacure’s proprietary technology comprised
of nicotinic acetylcholine receptor agonists and is the first
nicotinic receptor agonist in the clinic for this indication.
Phase II proof-of-concept studies are ongoing to assess the
anti-inflammatory, bronchodilating and bronchoprotective properties
of ASM-024 administered by inhalation.
Asmacure is a privately held company located in Quebec City,
Canada. The major investors in Asmacure include Domain
Associates, Fonds Bio-Innovation and Innovatech Quebec. For
more information visit www.asmacure.com
Media Contacts:
Tiberend Strategic Advisors, Inc.
(212) 827-0020
Andrew Mielach,
amielach@tiberend.com
or
Claire Sojda,
SOURCE
